GlassScriptPhysician profile
Vanessa Padron
NPI 1316499627
$4,259.91
in general payments reported to CMS, 2019-2025
24 companies · $693 in 2025
The $693 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $832 · 2022: $1,507 · 2023: $553 · 2024: $675 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $591.55 | 2022 | |
| Janssen Biotech, INC. | $446.27 | 2021-2025 | Darzalex, Tecvayli, Rybrevant |
| Merz North America, INC. | $446.11 | 2022-2023 | |
| Amgen INC. | $392.67 | 2021-2022 | |
| Genentech USA, INC. | $365.80 | 2021-2022 | |
| Glaxosmithkline, LLC. | $249.91 | 2021-2022 | |
| Beigene USA, INC. | $188.37 | 2021-2022 | |
| Genmab U.S., INC. | $166.70 | 2023-2024 | Epkinly |
| Emd Serono, INC. | $127.66 | 2023 | Tepmetko, Bavencio |
| Sobi, INC | $125.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $124.91 | 2024 | Reblozyl |
| Seagen INC. | $122.07 | 2021 | |
| Alexion Pharmaceuticals, INC. | $121.84 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $121.81 | 2024 | Libtayo |
| Incyte Corporation | $117.64 | 2025 | Monjuvi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $114.33 | 2025 | Vyvgart |
| Bayer Healthcare Pharmaceuticals INC. | $103.59 | 2025 | |
| Abbvie INC. | $96.18 | 2023 | |
| Merck Sharp & Dohme LLC | $59.58 | 2022-2023 | Keytruda |
| Coherus Oncology, INC. | $54.70 | 2024 | |
| Janssen Scientific Affairs, LLC | $37.50 | 2023 | Darzalex |
| Kyowa Kirin, INC. | $37.46 | 2023 | Poteligeo |
| Jazz Pharmaceuticals INC. | $27.99 | 2025 | |
| Tersera Therapeutics LLC | $20.27 | 2025 | Zoladex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Padron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.